FDA Downgrades Fibromyalgia Therapy Device to Class II
Published Date: 6/26/2026
Rule
Summary
The FDA is officially classifying a computerized behavioral therapy device for fibromyalgia symptoms as a Class II device, meaning it meets safety and effectiveness standards with special controls. This change helps patients get easier access to this innovative treatment by reducing some regulatory hurdles. The new classification is effective June 26, 2026, and could speed up how quickly these devices reach the market without extra costs.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 2 costs, 1 mixed.
Device Reclassified to Class II — Easier Access
The FDA officially classified the computerized behavioral therapy device for treatment of fibromyalgia symptoms as Class II with special controls, effective June 26, 2026 (classification applicable May 9, 2023). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
510(k) Premarket Notification Is Required
FDA states that computerized behavioral therapy devices for fibromyalgia symptoms are subject to premarket notification requirements under section 510(k) of the FD&C Act (they have not been exempted under section 510(m)). Manufacturers must therefore submit a 510(k) to market these Class II devices.
New Special Controls: Clinical Data, Software, Labeling
FDA set special controls for this device type: clinical data must evaluate improvement in fibromyalgia symptoms and relevant adverse events; software verification, validation, and hazard analysis are required; and physician and patient labeling must include recommended treatment regimes (frequency and duration) and a summary of clinical data including adverse events.
Sets Predicate for Future Devices — Easier 510(k) Route
FDA states that when a device is classified into class II through the De Novo process, that device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process instead of a De Novo or PMA. This can reduce regulatory burdens for future device sponsors.
Prescription-Only Requirement Maintained
At the time of classification, the computerized behavioral therapy device for fibromyalgia symptoms is a prescription device intended to provide a computerized version of behavioral therapy. Prescription devices remain subject to prescription-only conditions and related labeling rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16420, Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
2026-16353, Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. GDUFA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize FDA to assess and collect fees to support human generic drug activities. The current legislative authority for GDUFA expires at the end of September 2027. At that time, new legislation will be required for FDA to continue to assess and collect generic drug user fees for future fiscal years. The FD&C Act directs FDA, following negotiations with the regulated industry and periodic consultations with other stakeholders, to present recommendations for reauthorization of the GDUFA program to the relevant Congressional committees, publish the recommendations in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.
2026-16209, Radiology Devices; Reclassification of Digital Breast Tomosynthesis System
The FDA wants to change how digital breast tomosynthesis (DBT) systems are classified, moving them from a strict, high-level category (Class III) to a more flexible one (Class II) with special safety rules. This affects companies making these breast imaging devices, making it easier and faster to get them approved. Comments on this change are open until October 9, 2026, so stakeholders should act fast to share their thoughts!
Previous / Next Documents
Previous: 2026-12900, Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Next: 2026-12902, Medical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Test
The FDA is officially putting the COVID-19 antibody (serology) test into a safer, easier-to-manage category called Class II, starting June 26, 2026. This change helps make sure the tests work well and are safe, while also making it simpler for companies to bring new and better tests to patients. If you’re a test maker or user, expect smoother rules and better access without extra costs or delays.